Title |
Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study
|
---|---|
Published in |
BMC Neurology, May 2017
|
DOI | 10.1186/s12883-017-0869-3 |
Pubmed ID | |
Authors |
Michail Vikelis, Emmanouil V. Dermitzakis, Konstantinos C. Spingos, Georgios G. Vasiliadis, George S. Vlachos, Evaggelia Kararizou |
Abstract |
Migraine is included in the top-ten disabling diseases and conditions among the Western populations. Non-invasive neurostimulation, including the Cefaly® device, for the treatment of various types of pain is a relatively new field of interest. The aim of the present study was to explore the clinical experience with Cefaly® in a cohort of migraine patients previously refractory or intolerant to topiramate prophylaxis. A prospective, multi-center clinical study was performed in patients diagnosed with episodic or chronic migraine with a previous failure to topiramate treatment requiring prevention with Cefaly® according to the treating physician's suggestion. A 1-month period of baseline observation was followed by a 3-month period of observation during the use of transcutaneous supraorbital nerve stimulation (t-SNS) with Cefaly® as the only preventive treatment. A small but statistically significant decline was shown over time in the number of days with headache (HA), the number of days with HA with intensity ≥5/10, and the number of days with use of acute medication after 3 months (p < 0.001 for all of the three changes). Twenty-three patients (65.7%) expressed their satisfaction and intent to continue treatment with Cefaly®. Compliance was higher among satisfied subjects compared to non-satisfied subjects. None of the explored factors were significantly associated with the reason for the failure of topiramate. Three-months of preventive treatment for episodic or chronic migraine with t-SNS proved to be an effective, safe and well tolerated option for the treatment of patients with migraine who were intolerant or did not respond to topiramate. ClinicalTrials NCT03125525 . Registered 21 April 2017. |
Twitter Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 50% |
Costa Rica | 1 | 25% |
Unknown | 1 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 50% |
Scientists | 2 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 1% |
Unknown | 79 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 12 | 15% |
Student > Bachelor | 9 | 11% |
Librarian | 7 | 9% |
Student > Postgraduate | 6 | 8% |
Student > Ph. D. Student | 4 | 5% |
Other | 15 | 19% |
Unknown | 27 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 23 | 29% |
Nursing and Health Professions | 10 | 13% |
Neuroscience | 7 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Arts and Humanities | 1 | 1% |
Other | 7 | 9% |
Unknown | 30 | 38% |